论文部分内容阅读
目的评价莫西沙星序贯治疗慢性阻塞性肺疾病急性加重(AECOPD)的疗效和安全性。方法将68例AECOPD随机分入莫西沙星序贯治疗组(34例)和对照组(34例),治疗组给予莫西沙星0.4g静脉滴注,1次/d,3～5d后改为莫西沙星0.4g口服,1次/d,总疗程7～10d。对照组给予0.9%氯化钠溶液100ml+头孢呋辛钠1.5givgttq8h,联合0.9%氯化钠溶液250ml+阿奇霉素0.5givgttq24h,总疗程7～10d,分别观察两组的临床总有效率,细菌清除率,不良反应发生率,并进行效果分析。结果治疗组和对照组的临床总有效率分别为94.18%和82.35%,细菌清除率分别为86.67%和71.43%,不良反应发生率分别为5.88%和11.76%,两组比较均显著性差异(P<0.05)。结论莫西沙星序贯治疗AECOPD疗效显著,不良反应轻微,痛苦小,依从性好,细菌清除率高,可以延长再次发病间期,优于传统抗菌药物全程静脉给药,更应该作为AECOPD的优选治疗方案。
Objective To evaluate the efficacy and safety of sequential treatment of Moxifloxacin for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Sixty-eight AECOPD patients were randomly divided into sequential treatment group (n = 34) and control group (n = 34). Moxifloxacin 0.4g was given intravenously once a day for 3 to 5 days in the treatment group Moxifloxacin 0.4g orally, 1 time / d, the total duration of 7 ~ 10d. The control group was given 0.9% sodium chloride solution 100ml + cefuroxime sodium 1.5givgttq8h, combined 0.9% sodium chloride solution 250ml + azithromycin 0.5givgttq24h, the total duration of treatment 7 ~ 10d, respectively, the two groups were observed in the total effective rate of bacterial clearance, poor Reaction rate, and the effect analysis. Results The total effective rates of the treatment group and the control group were 94.18% and 82.35% respectively, the bacterial clearance rates were 86.67% and 71.43%, and the incidences of adverse reactions were 5.88% and 11.76% respectively. There were significant differences between the two groups P <0.05). Conclusion Sequential treatment of moxifloxacin has a significant curative effect on AECOPD with mild adverse reactions, low pain, good compliance and high bacterial clearance, which can prolong the period of re-onset of disease and is superior to the traditional intravenous antibiotics Treatment programs.